Bhavinkumar Dalal, MD
Pulmonary Disease · Royal Oak, MINPI 1477701878
Payments from drug & device makers
Across 70 payments — averaging $309.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$12K
- Inari Medical, Inc.$4K
- United Therapeutics Corporation$3K
- Regeneron Healthcare Solutions, Inc.$2K
- Actelion Pharmaceuticals US, Inc.$773
- GSK$225
- plus $519 from 7 others
What the payments were for
- Consulting fees$3,69417%
- Speaking & faculty fees$13,70063%
- Travel & lodging$9795%
- Food & beverage$3,30615%
- Education$60%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 27 | $11,801 |
| Inari Medical, Inc. | 2 | $4,128 |
| United Therapeutics Corporation | 9 | $2,569 |
| Regeneron Healthcare Solutions, Inc. | 5 | $1,669 |
| Actelion Pharmaceuticals US, Inc. | 14 | $773 |
| GSK | 2 | $225 |
| Genentech USA, Inc. | 1 | $140 |
| Insmed, Inc. | 4 | $140 |
| Merck | 1 | $81 |
| Sanofi | 2 | $56 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $45 |
| La Jolla Pharmaceutical Company | 1 | $40 |
| Verona Pharma, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$10,924
- CT THROMBECTOMY SYSTEM KIT$4,128
- FLOWTRIEVER CATHETER, S$4,128
- DUPIXENT$1,500
- UPTRAVI$242
- TRELEGY ELLIPTA$225
- OPSUMIT$128
- BREZTRI$119
How this compares
$21,684 in reported general payments places this provider in the 85th percentile of 463 pulmonary disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 15 | $117,623 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $3,810 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 23 | $840 |
| Montelukast Sodium | 37 | $372 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Royal Oak
- Enrique Calvo AyalaRoyal Oak$104K
- Njira LugogoAnn Arbor$12.9M
- Timothy BlackwellAnn Arbor$2.5M
- Kevin FlahertyAnn Arbor$2.3M
- Meilan HanAnn Arbor$1.8M
- Gary FergusonLivonia$1.5M
- Justin OldhamAnn Arbor$1.4M
- Robert PaineAnn Arbor$1.3M
- Irina ShanidzeFarmington Hills$1.2M
- Oscar Parodi Ortiz de VillateWarren$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.